Endocrine Abstracts

Glioblastoma (GBM) is the most prevalent and most lethal primary brain endocrine-related cancer (ERC) in adults which, in addition to the late-stage diagnosis and the lack of effective novel therapies, results in the low quality of life of patients and the poor prognosis, with a median survival from 10 to 14 months after diagnosis. Accordingly, the identification of novel molecular biomarkers of diagnosis and/or prognosis, as well as therapeutic targets becomes crucial to comb...

Pituitary tumours (PTs) constitute approximately 15% of all brain tumours, affecting up to 5% of the general population. The majority of PTs are hormonally active tumours (approximately 70%), resulting in significant comorbidities associated with hormone release. Furthermore, clinically non-functioning PTs (NFPTs, around 30%) exhibit mass effect-related comorbidities due to delayed diagnosis, despite lacking a link to hormone excess. Recent studies indicate that aberrant alter...

Intracranial Tumors comprise a diverse group of endocrine-related tumors [ERTs; e.g. craniopharyngiomas (CPs) and pituitary-tumors (PTs)], representing significant challenges for the diagnosis/prognosis/treatment of patients, their families and health systems due to their heterogeneity, associated neurological impairment and endocrine comorbidities. However, despite recent advances, the current treatment (e.g. surgery plus irradiation in CPs, pharmacological treatment with som...